Business
Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
New research collaboration with a Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human healthExpanded licensing agreement with Rubic
About this update from Dyadic International, Inc.
[{"type":"text","content":"New research collaboration with a Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human healthExpanded licensing agreement with Rubic One Health (“Rubic”) to develop, manufacture and commercialize affordable vaccines and biologics for human and animal health for African ContinentExpanded collaboration with Phibro/Abic animal health to develop vaccines for animal diseasesFully funded co-development and marketing agreement with Fermbox to use Dapibus™ platform to develop and commercialize animal free alternative proteins and biomaterialsNo serious adverse events or local and systemic side effects reported after completion of dosing of DYAI-100 recombinant protein RBD booster vaccine. Preliminary safety assessment report is expected in June 2023Commercial product portfolio expanded for pharmaceutical and non-pharmaceutical applicationsSelected by BARDA and FDA as one of six companies to present at the FDA Recombinant Protein-Based COVID-19 Vaccines Workshop in April 2023Multiple grant applications submitted for Sudan Ebola virus, Marburg virus, RVFV, WNV, ZIKA, TBEV and second generation COVID-19 vaccine candidatesReceived notice of allowance from the U.S. Patent and Trademark Office for “Production of Flu Vaccine in Myceliophthora thermophila” patent applicationReceived approximately $1.27 million from sale of minority equity interest in Alphazyme, LLCReceived first milestone payment from collaboration with global food ingredient company in April 2023Revenue increased 50.9% YoYCash and investment grade securities of $11.8 million as of March 31, 2023New corporate website to reflect our scientific development and expanded market focusFinancial results and business update conference call scheduled for 5:00 pm ET today JUPITER, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced its financial results for the first quarter of 2023, and highlighted recent company developments. “Dyadic is off to a great start in 2023, delivering multipl...